Dr. Jurcic on the Next Steps for Radioimmunotherapy

Joseph Jurcic, MD
Published: Monday, Jun 30, 2014

Joseph Jurcic, MD, head, Hematologic Malignancies, Columbia University Medical Center, discusses the next steps for research into radioimmunotherapy.

Radioimmunotherapy holds promise in multiple applications, Jurcic says. Preclinically, this therapy is being applied as conditioning for stem cell transplant. Encouraging results have been seen with beta-emitters.

Radioimmunotherapy may also be beneficial when using alpha particles to reduce toxicity yet gain an anti-tumor effect. In general, increasing the delivery of isotope to tumor cells but avoid toxicity has shown promise in preclinical studies.

Joseph Jurcic, MD, head, Hematologic Malignancies, Columbia University Medical Center, discusses the next steps for research into radioimmunotherapy.

Radioimmunotherapy holds promise in multiple applications, Jurcic says. Preclinically, this therapy is being applied as conditioning for stem cell transplant. Encouraging results have been seen with beta-emitters.

Radioimmunotherapy may also be beneficial when using alpha particles to reduce toxicity yet gain an anti-tumor effect. In general, increasing the delivery of isotope to tumor cells but avoid toxicity has shown promise in preclinical studies.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x